SEC Form 4 · accession 0001209191-19-018118
Eton Pharmaceuticals, Inc. · ETON
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Paul V Maier
Director
Period of report
Feb 20, 2019
Accepted (ET)
Mar 8, 2019 · 4:34 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001710340
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy)F1 | $7.31 | Feb 20, 2019 | A | 12,500 | A | — | Feb 19, 2029 | Common Stock | 12,500 | 12,500 | D |
Explanation of responses
- F1The shares subject to the option shall vest on a quarterly basis over 12 months from the date of grant until fully vested and exercisable on February 20, 2020.